While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel ...

Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Texas, USA-based biopharma Lexicon Pharmaceuticals (Nasdaq: LXRX) was trading nearly 36% lower on Friday morning.

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

Lexicon Pharmaceuticals shares tumbled in premarket trading Friday after a Food and Drug Administration advisory committee's negative vote on the biopharmaceutical company's Zynquista as an adjunct to ...

Lexicon Pharmaceuticals received a negative vote from a Food and Drug Administration advisory committee for Zynquista as an adjunct to insulin therapy for glycemic control in adults with Type 1 ...

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s ...

The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic ...

Lexicon did manage to get approval for type 1 diabetes in Europe, but the product was never launched there for commercial ...

Lexicon Pharmaceuticals Inc. (LXRX) announced that the U.S. Food and Drug Administration's Advisory Committee voted against the ...